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Recent insights in vaccine delivery point out a distinct benefit for antigen to be delivered in 
a microparticulate form to professional antigen presenting cells. Encapsulation technology to produce 
antigen laden microparticles often requires complex handlings involving the use of organic solvents, 
chemical reactivity and/or high shear forces. These issues impair the practical and economical feasibility 
of such delivery systems. In this paper, we introduce a novel concept for the encapsulation of antigen 
within microparticles, making use of the lower critical solution temperature (LCST) behavior of 
a thermosensitive carrier polymer. Particle fabrication and characterization is demonstrated 
as well as their uptake by dendritic cells. 
 
Introduction 
Current insights in immunology, especially in how the immune 
system recognizes pathogens and translates this into the induction 
of the appropriate adaptive immune response, pave the way 
for a more rational vaccine design.1–4 Besides the choice of the 
antigen and the addition of immunopotentiators, it has become 
clear that also the way this antigen is delivered to the immune 
system dramatically affects the outcome of immunisation. 
Generally speaking, at least three major advantages of 
microparticulate antigen delivery can be defined. First, encapsulation 
in particles with sizes varying from 1–10 mm increases, 
due to cell type dependent size limitations, their uptake by 
professional antigen presenting cells such as dendritic cells 
(DC’s). Second, uptake of antigens in a particulate form appears 
to strongly augment antigen presentation via MHCI (major 
histocompatibility complex I), a feature hardly achievable when 
using soluble antigens. MHCI mediated presentation is crucial 
for the induction of CD8 cytotoxic T cell responses, which can 
recognize and kill virally infected or malignant cells. Third, the 
potency of an immune response is strongly increased when both 
antigen and adjuvant are co-delivered to the same intracellular 
compartment of the same antigen presenting cell. This means 
that strategies allowing an efficient co-encapsulation of antigen 
and immunopotentiator in the same particle could strongly 
enhance vaccine efficiency. These requirements for improved 
vaccination are not met by traditional vaccination strategies 
which commonly involve the use of aluminium salts or oil/water 
emulsions, merely generating a depot effect. 
Drug delivery scientists have developed a myriad of particulate 
delivery systems to encapsulate antigens in micro- and nanoparticles 
to enhance the induced immune response.5–13 The main 
drawback of these approaches is most often the use of organic 
solvents, harsh chemical reactions, long lasting shear forces and 
the involvement of a multitude of batch operation steps before 
obtaining the final antigen formulation. These issues severely limit 
the batch-to-batch reproducibility of the developed delivery 
system, while the complexity of the process hampers the feasibility 
of any clinical trial or large scale production. Therefore, there is 
a clear need for single step processes which can generate stable, 
antigen-laden particles with such dimensions (i.e. sub-10 mm) that 
they are efficiently taken up by antigen presenting cells. 
In this paper, we report on a simple yet efficient method to 
produce antigen-laden microparticles, which are stable both in 
dry state as well as in water in physiological conditions. The 
novelty of the concept lies in the use of a lower critical solution 
temperature (LCST) behaving polymer as excipient in combination 
with spray drying as particle producing technique. Below 
the LCST of the polymer excipient, the aqueous feed is a clear 
antigen/polymer solution, while the obtained spray dried 
microparticles form a colloidal stable suspension in aqueous 
medium at physiological temperature (i.e. 37 _C; above the LCST 
of the polymer excipient). 
 
 
Fig. 1 Chemical structure of polyNIPAA. 
 
In this study, we use poly(N-isopropylacrylamide) (poly- 
NIPAA) as model LCST polymer. The chemical structure of 
polyNIPAA is shown in Fig. 1, while Fig. 2 schematically 
represents the desired behavior of the microparticles in aqueous 
medium at different temperatures. PolyNIPAA is the classic 
example of a polymer exhibiting LCST behavior.14–19 This means 
that below a certain temperature (i.e. the LCST; 32 _C for 
polyNIPAA) the polymer is hydrated and fully water soluble, 
while upon increasing temperature the entropy of the solvent 
molecules becomes that high that the polymer is no longer 
hydrated and becomes hydrophobic. The consecutive process of 
chain collapse and aggregation, forming microparticles can be 




Ovalbumin (OVA; grade III), fluorescein isothiocyanate (FITC) 
and poly(N-isopropylacrylamide) (polyNIPAA; Mw _ 20–25 
kDa) were purchased from Sigma-Aldrich. Mannitol (C* 
Mannidex 16700) was donated by Cerestar. FITC labeled OVA 
was synthesized by mixing OVA and FITC in a borate buffer at 
pH 8.5 followed by extensive dialysis and lyophilisation. 
 
Microparticle spray drying 
An aqueous solution of OVA, polyNIPAA and mannitol (OVA/ 
polyNIPAA/mannitol ratio: 1/5/15, total solid content: 4.0% 
w/w) was prepared. Spray drying of this solution was performed 
in a lab-scale spray dryer, type B290 (Bucchi). The solution was 
fed to a two-fluid nozzle (diameter 0.7 mm) at the top of the spray 
dryer. In addition, the spray dryer operated in co-current air 
flow. This aqueous solution was spray dried according to the 
process parameters shown in Table 1. 
The spray dried particles were collected in a reservoir attached 
to a cyclone, cooled down to room temperature and stored in 
sealed vials (room temperature, ambient relative humidity) prior 
to their characterisation and further use. Fluorescent microparticles 
were prepared using a mixture of 180 mg OVA and 20 mg 
of FITC-OVA. 
 
Bone-marrow derived DCs (BM-DCs) 
Female C57BL/6 mice were purchased from Janvier (Le Genest 
Saint Isle, France) and housed in a specified pathogen-free 
facility in micro-isolator units. Dendritic cells were generated 
using a modified Inaba protocol.20 Two to six months C57BL/6 
mice were sacrificed and bone marrow was flushed from their 
femurs and tibias. After lysis of red blood cells with ACK lysis 
buffer (BioWhittaker, Wakersville, MD), granulocytes and B 
cells were depleted using Gr-1 (Pharmingen) and B220 (Pharmingen) 
antibodies, respectively, and low-toxicity rabbit 
complement (Cedarlane Laboratories Ltd., Hornby, Ontario, 
Canada). Cells were seeded at a density of 2 _ 105 cells ml_1 in 
175 cm2 Falcon tubes (Becton Dickinson) in DC medium (RPMI 
1640 medium containing 5% LPS-free FCS, 1% penicillin/streptomycin, 
1% L-glutamine and 50 mM b-mercaptoethanol) containing 
10 ng ml_1 IL-4 and 10 ng ml_1 GM-CSF (both from 
Peprotech, Rock Hill, NJ). After two days and again after four 
days of culture, the non-adherent cells were centrifuged, resuspended 
in fresh medium and replated to the same Falcon tubes. 
On the sixth day, non-adherent cells were removed and fresh 
medium containing 10 ng ml_1 GM-CSF and 5 ng ml_1 IL-4 was 
added. On day 8 of culture, non-adherent cells were harvested 
and used for the experiments. 
 
Uptake and cytotoxicity assays 
Cells were washed, fixed with 4% paraformaldehyde, stained with 
alexa 488 cholera toxin subunit B (5mg ml_1, Molecular Probes) 
and visualized by confocal microscopy. Nuclei were stained with 
DAPI (1 mM). Flow-cytometry samples were measured on 
a FACSCalibur (BD) flow cytometer and analyzed using Cell- 
QuestTM software. 
Cytotoxicity was assessed using a classical p-nitrophenyl 
phosphate (pNPP) cell viability assay. Human dermal fibroblasts 
(ATCC CRL-2522) were seeded in a 96-well plate at 2.5 103 cells 
per well and incubated for 6 h with the spray dried microparticles 
at different concentrations followed by medium renewal and 
a further 2 days of culturing. Subsequently, the cell medium was 
removed and 50 ml of pNPP assay solution was added followed 
by incubation at 37 _C and 5% CO2. After 2 h the reaction was 
stopped by addition of NaOH and the absorbance was measured 
spectrophotometrically at 405 nm. 
 
Characterization 
Optical microscopy images were recorded on a Nikon EZ-C1 
confocal microscope. Scanning electron microscopy (SEM) 
images were recorded at 5 kV acceleration voltage on a Quanta 
FEG FEI scanning electron microscope applying a gold/palladium 
sputtering prior to SEM imaging. Dynamic light scattering  
was performed on a Malvern Nanosizer. Protein content was 
measured by Bio-Rad Protein Assay. ATR-FTIR spectra were 
recorded on Biorad 930C apparatus using the Golden Gate 
accessory (diamond crystal). 32 scans were performed at a resolution 
of 4 cm_1. 
 
Fig. 2 Schematic representation of the physicochemical behavior of the 
thermosensitive antigen-laden microparticles. In dry state the microparticles 
consist of collapsed polyNIPAA molecules (red curves) encapsulating 
the OVA (green curves) with mannitol (orange spots) as additional 
excipient distributed throughout the volume of the particles. Upon 
suspension in water (light blue discs) above the LCST of polyNIPAA, the 
polyNIPAA molecules retain their collapsed formulation still encapsulating 
the OVA. The low molecular weight mannitol remains partly 
bound to the particles and partly goes into solution. When the temperature 
of the aqueous medium is below the LCST of the polyNIPAA, the 
polyNIPAA chains are hydrated and all components go in solution. 
 
Table 1 Process conditions during spray drying in the lab scale spray 
dryer, type B290 
Process parameters Process 
Inlet drying air temperature 130 _C 
Outlet drying air temperature 65 _C 
Drying air gas rate 35 m3 h_1 
Atomising nitrogen pressure 0.3 bar 
 
Results and discussion 
In our set-up a clear solution of polyNIPAA, ovalbumin (OVA) 
and mannitol was fed at room temperature (i.e. below the LCST 
of the polyNIPAA) to a bench top spray dryer. Mannitol is 
a polyol that is often used as excipient in pharmaceutical applications 
to stabilize sensitive drug molecules and due to its relatively 
low hydroscopicity which prevents spray-dried 
micropartciles from sticking. OVA is a 43 kDa protein derived 
from chicken egg white and is commonly used as model antigen 
in mechanistic immunological research. 
The obtained product (process yield: 39%) was a white 
powder with a mean particle diameter of 4.5 mm as determined 
by image analysis. The particle morphology was assessed by 
scanning electron microscopy (SEM). The corresponding 
images are shown in Fig. 3A-B and reveal a rather irregular 
shape of the microparticles, typical for polymer-based spray 
dried formulations. 
The powder was readily soluble in water at room temperature 
(i.e. below the LCST of polyNIPAA) but formed a turbid 
suspension when the powder was reconstituted with water 
heated above the LCST of polyNIPAA. Addition of mannitol 
to the feed solution prior to spray drying was required in order 
to allow redispersion of the powder in water above the LCST of 
polyNIPAA. In absence of mannitol or when using another 
excipient (e.g. maltodextrin), large aggregated clumps were 
formed when attempting to redisperse in water above the LCST 
of polyNIPAA. The temperature-dependent behavior of the 
produced microparticles was monitored by measuring the 
transmittance of UV/VIS light as a function of temperature and 
the recorded curves are shown in Fig. 4. The inset of Fig. 4 
shows the transmittance of polyNIPAA in water as a function 
of the temperature. A steep decrease in transmittance is 
observed at around 32 _C, which is well known for polyNIPAA. 
The transmittance of the microparticles suspended in water at 
40 _C (blue curve with cubic symbols going from right to left) 
indicates a moderately turbid solution. Upon decreasing 
temperature the transmittance increases until a clear solution is 
obtained at around 31 _C. Interestingly, the shift in transmittance 
occurs more gradually than in the case of pure poly- 
NIPA, which is likely due to physico-chemical interactions such 
as H-bonding and hydrophobic interactions, between the 
polyNIPA and the OVA and mannitol, respectively. The 
formation of H-bonding between the NH group of polyNIPA 
and carboxylic acids is well known.21,22 This is expected as well 
in our system as OVA contains many carboxylic acid bearing 
aminoacids Moreover, hydrophobic interactions with more 
hydrophobic domains in OVA are likely to occur as well. Since 
in our case we are dealing with a complex mixture, it is difficult 
to elucidate the exact contribution of the respective interactions. 
However, ATR-FTIR spectroscopy shows that the intensity 
ratio of the amide I (C]O; n ¼ 1650 cm_1) to the amide II 
peak (NH; n ¼ 1545–1516 cm_1) was significantly higher for 
the spray-dried microparticles compared to the native 
polyNIPA and OVA. According to literature this is indicative 
of the presence of H-bond and/or hydrophobic interactions 
between the different components within the spray-dried 
microparticles.22 
When the same solution is reheated to 40 _C (red curve with 
circular symbols going from left to right), as expected, a shift in 
transmittance is observed at around 32 _C but a much lower 
transmittance at 40 _C is observed as compared to the transmittance 
of the starting suspension at 40 _C. When again the 
temperature is decreased (black curve with triangular symbols 
going from right to left), the transmittance follows an identical 
track as the previous heating track (red curve with circular 
symbols). Also, these two curves (red and black) show a more 
gradual shift in transmittance than the pure polyNIPAA, again 
most likely due to interactions with the OVA and mannitol, 
respectively. The observed lower transmittance of the suspension 
obtained upon reheating as compared to the transmittance 
of the original starting suspension at 40 _C is further confirmed 
visually, as shown in Fig. 4 with photographs of the liquids at 
different stages of the heating/cooling cycle. A moderately 
turbid suspension upon redispersing of the powder in water at 
40 _C, a clear solution at room temperature and a strongly 
turbid solution upon reheating to 40 _C are observed. The 
reason for this behavior is revealed by SEM and dynamic light 
scattering showing a much lower particle size (i.e. 120 _ 34 nm) 
of the reheated suspension (Fig. 3C) compared to the original 
starting suspension (Fig. 3A-B). For the same mass of materials 
this corresponds to a much higher amount of particles in 
case of the reheated suspension and thus a decrease in light 
transmittance. 
 
Fig. 3 Scanning electron microscopy (SEM) images of the spray dried 
microparticles (A) as such after spray drying and (C) after a reheating 
cycle. (B) and (C) show the corresponding size distribution curves of (A) 
spray dried microparticles as measured by image analysis and (C) 
reheated particles as measured by dynamic light scattering (DLS). 
 
The particle disassembly upon temperature decrease was 
imaged by optical microscopy. A drop of heated microparticle 
suspension was put onto a coverslip under a confocal microscope 
and snapshots were taken at regular time intervals while the 
droplet was cooled spontaneously by interaction with the 
ambient environment. As shown in Fig. 5, the particle 
(the darkish color is most likely due to the non-hydrated interior 
of the particle) gradually decreases in size until it is completely 
dissolved. 
The encapsulation efficiencies in dry and wet state were determined 
separately. Encapsulation of OVA in the dry powder was 
determined by dissolving a known amount of powder at room 
temperature and measuring the amount of protein by Bradford 
protein assay,23 revealing an encapsulation efficiency of 48 _ 6%, 
relative to the protein concentration in the feed streamprior tospray 
drying. Release of OVA from the microparticles when suspended 
above the LCST of polyNIPA was measured by filtering the 
microparticle suspension at 40 _C and measuring the amount of 
protein in the filtrate by Bradford protein assay. No protein was 
detected in this filtrate showing excellent retention of the protein 
within themicropartcles upon suspension inwater above the LCST. 
Confocal microscopy (Fig. 6A) and flow cytometry (Fig. 6B) 
allowed to assess the uptake of the particles by bone marrowderived 
mouse dendritic cells (DCs). This cell type was chosen to 
study microparticle internalization as DCs are professional 
antigen presenting cells and thus the primary target cells for 
vaccine delivery systems. For this purpose, fluorescent microparticles 
were produced by adding an amount of fluorescein 
isothiocyanate-labeled ovalbumin (FITC-OVA) to the feed 
solution prior to spray drying. The thus obtained powder had 
a yellowish color and was green-fluorescent upon illumination 
with 488 nm light. During addition of the microparticles to the 
cultured DCs, care was taken in order to ensure a constant 
temperature of 37 _C of both the microparticle suspension and 
the cell medium, in order to avoid dissolution of the microparticles 
due to a temperature drop. The confocal image is shown in 
Fig. 6A and is recorded 4 h after the incubation of the DCs with 
the microparticle suspension. The cell nuclei were stained blue 
with DAPI and the cell membrane was stained red with Alexa594 
labeled cholera toxin B subunit. In this image, it is clear that the 
green fluorescent microparticles are efficiently taken up by the 
DCs. This was further confirmed by flow cytometry (Fig. 6B) 
 
Fig. 4 Transmittance plots of the microparticle suspension recorded at decreasing temperature (,), followed by 
increasing temperature (B) and again decreasing temperature (O). The inset shows the transmittance plot of pure 
polyNIPAA. Next to the curves, photographs are shown of the corresponding liquids. 
 
Fig. 5 Optical microscopy snapshots of the temperature induced dissolution of the spray-dried microparticles. A 
drop of microparticle suspension at a temperature above the LCST of polyNIPAA was placed on a cover slip imaged 
by a confocal microscope at room temperature. The effect of the gradual decrease of the aqueous medium towards 
room temperature was monitored by taking snapshots at 5 s time intervals. 
 
showing an increasing shift in fluorescence with the concentration 
of added microparticles. Cytotoxicity of the microparticles 
was assessed on a human dermal fibroblast cell line by a common 
pNPP cell viability assay. This cell type was chosen because it is 
abundantly present subcutaneous (i.e. a common administration 
route for vaccine delivery). The graphs shown in Fig. 6C show no 
detectable cytotoxicity of the microparticles at moderate 
concentrations and only a slight decrease in cell viability in the 
case of microparticle concentrations as high as 4 mg ml_1. 
 
Conclusions 
In this paper, we have demonstrated a simple and efficient 
method for producing antigen laden microparticles with 
dimensions allowing uptake by antigen presenting cells. Our 
main concept is the use of a difference in physicochemical 
conditions (i.e. temperature in this case) between the spray 
drying feed stream (room temperature of 25 _C) and the final 
medium in which the particles are suspended (i.e. physiological 
conditions exhibiting a temperature of 37 _C). Therefore we 
used the LCST phenomenon, allowing the production (starting 
from a clear feed solution) of solid microparticles, which can be 
resuspended at temperatures above the LCST of the carrier 
polymer and readily dissolve below the LCST. Our approach 
has two main assets. The first one is the simplicity of our 
production process. Spray drying is a continuous, single-step 
processing technique,24,25 which can be scaled up easily, allowing 
large-scale industrial production of our antigen laden 
microparticles. The second asset is the possibility to incorporate 
an almost unlimited variety of additional components within 
the microparticles. This allows simultaneous incorporation of 
additional adjuvants into the microparticles, making this technology 
a general platform for the production of vaccines, thus 
allowing one to modulate the induced immune response by 
varying the microparticles’ content. Also, additional excipients 
can be easily incorporated, which might further enhance antigen 
stability in a dry formulation. 
 
 Fig. 6 (A) Confocal microscopy image of bone marrow derived dendritic cells (DC’s) incubated with the 
microparticles. The cell nuclei were stained blue with DAPI, the cell membrane was stained red with Cy5 labeled 
cholera toxin B subunit and the microparticles were fluorescent green. (B) Corresponding flow cytometry histogram 
of dendritic cells incubated with different amounts of fluorescent microparticles. (C) Cell viability data of the 
microparticles determined using a standard pNPP assay. 
 
We are fully aware of the fact that poyNIPAA is not biodegradable 
and thus antigen release will not spontaneously 
occur under physiological conditions. However, with this 
explorative study, we aimed to demonstrate a proof-of-concept 
(using a model LCST polymer). Further studies will 
focus on the use of biodegradable LCST polymers (e.g. polyhydropropylmethacrylamide- 
dilactate (polyHPMA-lac2) which 
consist of polyHPMA with pending lactate groups).26 This 
polymer, having two lactate moieties substituted on the hydroxyl 
group of each repeating unit, has an LCST of 15 _C which 
increases to 62 _C upon hydrolysis of a lactate unit. This 
approach would allow the production of microparticles which 
are stable above the LCST but which gradually dissolve due to 
hydrolysis of the LCST polymer. 
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